Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5270365
Max Phase: Preclinical
Molecular Formula: C15H14Cl2N4O3S
Molecular Weight: 401.28
Associated Items:
ID: ALA5270365
Max Phase: Preclinical
Molecular Formula: C15H14Cl2N4O3S
Molecular Weight: 401.28
Associated Items:
Canonical SMILES: O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(c2ncc([N+](=O)[O-])s2)CC1
Standard InChI: InChI=1S/C15H14Cl2N4O3S/c16-11-2-1-10(7-12(11)17)8-13(22)19-3-5-20(6-4-19)15-18-9-14(25-15)21(23)24/h1-2,7,9H,3-6,8H2
Standard InChI Key: LRRDLMAWQBVANX-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 401.28 | Molecular Weight (Monoisotopic): 400.0164 | AlogP: 3.25 | #Rotatable Bonds: 4 |
Polar Surface Area: 79.58 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.65 | CX LogD: 3.65 |
Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.58 | Np Likeness Score: -2.02 |
1. Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ.. (2023) Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633., 86 [PMID:37148788] [10.1016/j.bmc.2023.117295] |
Source(1):